key: cord-0965204-z0lbmy4r
authors: Ozbalci, Demircan; Doguc, Duygu Kumbul; Yilmaz, Gulruhsar; Ozturk, Onder; Sirin, Fevziye Burcu; Akcam, Fusun Zeynep
title: Interference of D‐dimer levels from heterophilic antibody in COVID‐19: A serious concern in treatment and follow‐up of patients
date: 2021-08-18
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13654
sha: 3bcf73104537b0da197e9b2855ae33af8f4bf7b0
doc_id: 965204
cord_uid: z0lbmy4r

COVID-19 has become a pandemic since March 11, 2020 and caused devastating effects with high death rates worldwide. COVID-19 has led to severe coagulopathy, and thus routine coagulation assays have been recommended to evaluate coagulation deficiency [1]. D-Dimer has been used as a biomarker of coagulopathy from the beginning of the pandemic which has become an important tool of follow-up in COVID-19 as the elevation of D-Dimer has been directly correlated with poor prognosis [2]. D-Dimer levels guide physician to determine which patients should receive LMWH therapy [2, 3].

Dear Editors, COVID-19 has become a pandemic since 11 March 2020 and caused devastating effects with high death rates worldwide. COVID-19 has led to severe coagulopathy, and thus, routine coagulation assays have been recommended to evaluate coagulation deficiency. 1 D-dimer has been used as a biomarker of coagulopathy from the beginning of the pandemic, which has become an important tool for follow-up in COVID-19 as the elevation of D-dimer has been directly correlated with poor prognosis. 2 D-dimer levels guide a physician to determine which patients should receive LMWH therapy. 2, 3 From the beginning of the pandemic, we dealt with very high levels of D-dimer (>20.000 ng/mL) in some of the COVID-19 patients during their hospitalizations. Those D-dimer tests were re-assayed, and serial dilutions were made, but the results were still elevated and were higher than 20.000 ng/mL D-dimer Units (D-DU). In some of them, D-dimer levels were persistently elevated despite no abnormalities were found related to this elevation. It has been reported that, along with some laboratory tests such as ACTH, troponin and prostate-specific antigen, false D-dimer elevations could be seen in patients with viral infections because of heterophilic antibodies but data on COVID-19 were not available up to now. 4, 5 Heterophilic antibodies are polyclonal, heterogenous antibodies that bound to animal antigens. They can either be IgG or IgM type and may be induced by viral, bacterial infections, malignancies, autoimmune disorders, after vaccinations or produced without any apparent cause. 6 They are more common in debilitated and hospitalized patients (0.2%-15%) but in general population, its prevalence is about 0.5%-3%. 6 In this paper, we want to represent two PCR-positive COVID-19 cases with isolated and persistently elevated D-dimer without obvious cause after discharge from hospital. In both cases, serial dilutions (1/2, 1/10 and 1/20) were performed to rule out assay interference, and similar recovery percentages (90%-120%) were shown which reflected us that there was no assay interference (Table 1) . Tests for lupus anticoagulant, antinuclear, anti-cardiolipin antibodies and rheumatoid factor which might be responsible for positive interference were also analysed and were negative in both patients. Finally, a suspicion of heterophilic antibody interference was discussed with clinical laboratory.

The same plasma analysed for D-dimer in autoanalyzer was used for heterophilic antibody existence, which was incubated in heterophilic antibody-blocking tube (HBT) (Scantibodies Laboratory, Inc.) for an hour. Afterwards, the supernatant of plasma was transferred to a tube and analysed for D-dimer once again. In both cases, significant decrease in D-dimer levels was shown.

In the first case, a 54-year-old male patient, who had no history of chronic illness, was hospitalized with complaints of fever and shortness of breath and his chest computed tomography (CT) revealed bilaterally interstitial infiltration compatible to COVID-19 pneumonia. Complete blood count (CBC) was normal at the beginning, but D-dimer was elevated (Hb: 14.6 g/dL, Leu: 4.9 × well. Viral infections have been suggested to be responsible in most of cases, and also, blood transfusions, exposure to immune materials, dealing with animals or its products and dialysis have also been closely related to induce heterophilic antibodies as well. 5 In those cases, Ddimer levels have dramatically returned to normal after re-testing with antibody-blocking methods. 3, 8 The same mechanism may also be the fact in COVID-19. 9 In both cases, patients had high levels of D-dimer while testing for heterophilic antibody, and we suspected antibody interference while the usual normalization process of D-dimer prolonged. In case one, the D-dimer levels decreased but did not decline to normal level; however, in case two, D-dimer levels became normal after testing with heterophilic antibody blocking as in other cases related with viral infections. 8 We suggested that the difference in decrease rate in our cases may be related to heterogeneous nature of Although a small but not insignificant complication of bleeding in two retrospective studies was reported, LMWH therapy significantly reduced mortality in COVID-19 and had major therapeutic and immunomodulatory effects in COVID-19 beyond anticoagulation. 11, 12 Unawareness of the pseudo-elevation of D-dimer by heterophilic antibodies could lead to unnecessary treatment with LMWH and devastating results because of major haemorrhage.

In conclusion, elevated D-dimer levels in COVID-19 without any signs of thrombotic disease should prompt the physician to evaluate the case for heterophilic antibody. In these cases, somehow a kind of immunologic reaction may be triggered and caused de novo synthesis of antibodies against virus which may cause positive interference in D-dimer analysis. We cannot rule out that Ddimer plasma levels were actually elevated to some extent in those patients; heterophilic antibodies would have led to an overestimation; urgent studies are needed to explore the incidence and ethiology of this phenomenon.

coagulation, COVID-19, D-dimer, heterophilic antibodies

N/A. 

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

People's liberation army professional committee of critical care medicine, Chinese society on thrombosis and haemostasis. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Interference from heterophilic antibodies in D-dimer assessment. A case report

Identification of and solution for false D-dimer results

When lab tests lie … heterophile antibodies

Accurate Results in the Clinical Laboratory. A Guide to Error Detection and Correction

Clinical laboratory investigation of a patient with an extremely high D-dimer level: a case report

Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report

Viral antibodies in infectious mononucleosis

Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19

COVID-19 associated coagulopathy: thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy